BTG plc
 | |
| Public | |
| Traded as | LSE: BTG |
| Industry | Healthcare |
| Founded | 1991 as British Technology Group Ltd. |
| Headquarters | London, United Kingdom |
Key people | Garry Watts (Chairman of the board), Louise Makin (CEO), Rolf Soderstrom (CFO) |
| Products | Development, manufacturing and commercialisation of specialty pharmaceuticals and interventional medicine in the areas of critical care, cancer and varicose veins. BTG also has a revenue stream from royalty payments on partnered products. |
| Revenue | £367.8 million (2015)[1] |
| £67.9 million (2015)[1] | |
| Profit | £33.6 million (2015)[1] |
| Website | www.btgplc.com |
BTG plc is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians.
It trades as BTG International Inc. in the United States and as BTG International Ltd. in the United Kingdom.[2] The latter name arose as the result of the British Technology Group Ltd changing its name on 27 May 1998.[3] BTG is a constituent of the FTSE 250 Index.
History
In 1948, the National Research Development Corporation was formed with the purpose of commercialising innovations that arose from public funded research.[4] This was complemented in November 1975 by the establishment of the National Enterprise Board to implement the then-Government's policy of moving public sector industry into commercial private enterprise.[5]
These two organisations were merged by the Government in 1981 to form a new, non-statutory body called the British Technology Group.[6] It acted principally to license and commercialise the use of publicly funded developments. The Group was put onto a statutory footing in the British Technology Group Act 1991[7] with HM Treasury initially being the only shareholder. Subsequently, in March 1992, Cinven arranged a management buy-out from the Government. The company later floated on the London Stock Exchange in 1995.[4] Three years later, on 27 May 1998, the Group adopted its present name. It now focuses its work on developing and commercialising medical innovations.[4]
Since acquiring the commercialisation rights to magnetic resonance imaging (MRI) (under a revenue share scheme) in 1983, BTG has come to license a large part of the world market in MRI, including licensees such as General Electric and Philips.[8]
BTG plc completed the acquisition of Protherics PLC in December 2008 and of Biocompatibles International plc in January 2011.[9]
In May 2016 BTG plc acquired the Israeli company Galil Medical for 110 million dollar.[10]
Operations
BTG earns revenues from specialty pharmaceutical and interventional medicine product sales and on royalties from partnered products. The company has operations in Europe, North America and Australia.
See also
References
- 1 2 3 "Preliminary Results 2015" (PDF). BTG. Retrieved 28 March 2016.
- ↑ "BTG plc - Contact Us". btgplc.com. Retrieved 23 March 2015.
- ↑ "Companies House WebCheck". companieshouse.gov.uk. Retrieved 23 March 2015.
- 1 2 3 Overview of BTG International's history
- ↑ Elizabeth II (1975). The Industry Act, 1975. HM Stationery Office. ISBN 0-10-546875-4.
- ↑ Abstract of Department of Trade and Industry report "Monitoring of British Technology Group"
- ↑ "British Technology Group Act 1991". Legislation.gov.uk. Retrieved 6 May 2016.
- ↑ Case study of BTG's MRI licensing
- ↑ "BTG's £177m deal to buy cancer treatment firm Biocompatibles International". The Evening Standard. Retrieved 23 March 2015.
- ↑ BTG acquires Galil Medical for $110m, Globes, May 5, 2016
External links
|